Kezar Life Sciences Acquired by Aurinia Pharmaceuticals
Cooley advised Kezar Life Sciences, a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, on its agreement to be acquired by Aurinia Pharmaceuticals, a biopharmaceutical company focused on developing therapies to people living with autoimmune diseases with high unmet medical needs, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right.
The transaction was announced publicly in the Aurinia Pharmaceuticals' press release, which can be viewed here: Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Lead Team: Bill Roegge, Rita Sobral, Laura Berezin, Jaime Chase, and Parth Bhatt led the Cooley team advising Kezar Life Sciences.
Cooley previously advised Kezar Life Sciences on its $50 million Series B financing (2017), $75 million IPO (2018), and response to an unsolicited takeover proposal from Tang Capital Management, including its adoption of a shareholder rights plan.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.